FULC

Fulcrum Therapeutics Inc

NASDAQ: FULC · HEALTHCARE · BIOTECHNOLOGY

$6.96

+9.50% today

Updated 2026-06-05

Market cap

$245.88M

P/E ratio

—

P/S ratio

2.66x

EPS (TTM)

$-1.15

Dividend yield

—

52W range

$3 – $16

Volume

1.7M

Market cap

$245.88M

P/E ratio

—

P/S ratio

2.66x

EPS (TTM)

$-1.15

Dividend yield

—

52W range

$3 – $16

Volume

1.7M

WallStSmart proprietary scores

out of 100

Grade: D

Sell

Investment rating

3.7

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

10.3

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$6.62

-4.89%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy6 Buy1 Hold0 Sell1 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 10.30 — safe zone

+ Debt/equity 0.02x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-18.76M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$6.34M	$2.81M	$80.00M	$0.00	$0.00
Net income	$-109.87M	$-97.33M	$-9.72M	$-74.88M	$-18.89M
EPS	—	—	—	—	$-1.15
Free cash flow	$-99.01M	$-91.47M	$-2.50M	$-60.38M	$-18.76M
Profit margin	-1,732.43%	-3,470.05%	-12.16%	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-23	LEHRER-GRAIWER, JOSHUA	Buy	64,000	—
2026-02-02	TOURANGEAU, GREG	Buy	57,000	—
2026-02-02	SAPIR, ALEX	Buy	650,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
FULC	$245.88M	35	3.7	3.0	5.0	8.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Fulcrum Therapeutics Inc trades at $6.96. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 10.30, it sits in the safe zone.

Frequently asked questions

What is Fulcrum Therapeutics Inc's stock price?

Fulcrum Therapeutics Inc (FULC) trades at $6.96, on a P/S of 2.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is Fulcrum Therapeutics Inc overvalued?

Fulcrum Therapeutics Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Fulcrum Therapeutics Inc (FULC)?

The 12-month analyst consensus target is $6.62, about 4.9% below the current $6.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Fulcrum Therapeutics Inc's Altman Z-Score is 10.30, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio2.66x

ROE-22.84%

Beta2.92

50D MA$7.08

200D MA$8.77

Shares out0.07B

Float0.05B

Short ratio—

Avg volume1.7M

Performance

1 week-46.68%

1 month-47.36%

3 months-54.83%

YTD-67.37%

1 year—

3 years—

5 years—

Compare

FULC vs LLY →FULC vs JNJ →FULC vs ABBV →Stock screener →